comparemela.com
Home
Live Updates
Fusion to acquire radiologand therapy for prostate cancer : comparemela.com
Fusion to acquire radiologand therapy for prostate cancer
An IND application for an ongoing Phase II trial of an alpha-emitting radiopharmaceutical will be acquired by Fusion Pharmaceuticals.
Related Keywords
John Valliant ,
Oliver Sartor ,
Fusion Pharmaceuticals ,
European Commission ,
Tulane Cancer Center ,
Laborde Professor For Cancer Research ,
Laborde Professor ,
Cancer Research ,
Medical Director ,
Tulane Cancer ,
Chief Executive Officer ,
comparemela.com © 2020. All Rights Reserved.